Regeneron Pharmaceuticals, Inc. (REGN)
742.12
+3.40
(+0.46%)
USD |
NASDAQ |
Oct 07, 16:00
741.96
-0.16
(-0.02%)
After-Hours: 06:21
Regeneron Pharmaceuticals Market Cap : 76.74B for Oct. 7, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| October 07, 2026 | 76.74B |
| October 06, 2026 | 76.38B |
| October 05, 2026 | 75.12B |
| October 02, 2026 | 76.02B |
| October 01, 2026 | 75.98B |
| September 30, 2026 | 78.41B |
| September 29, 2026 | 77.60B |
| September 28, 2026 | 77.78B |
| September 25, 2026 | 81.48B |
| September 24, 2026 | 82.31B |
| September 23, 2026 | 82.91B |
| September 22, 2026 | 83.12B |
| September 21, 2026 | 82.53B |
| September 18, 2026 | 81.15B |
| September 17, 2026 | 81.63B |
| September 16, 2026 | 80.09B |
| September 15, 2026 | 80.04B |
| September 14, 2026 | 82.07B |
| September 11, 2026 | 80.81B |
| September 10, 2026 | 82.02B |
| September 09, 2026 | 83.51B |
| September 08, 2026 | 83.79B |
| September 04, 2026 | 85.59B |
| September 03, 2026 | 87.21B |
| September 02, 2026 | 88.10B |
| Date | Value |
|---|---|
| September 01, 2026 | 85.18B |
| August 31, 2026 | 82.62B |
| August 28, 2026 | 82.12B |
| August 27, 2026 | 83.52B |
| August 26, 2026 | 84.25B |
| August 25, 2026 | 86.19B |
| August 24, 2026 | 85.67B |
| August 21, 2026 | 86.24B |
| August 20, 2026 | 85.47B |
| August 19, 2026 | 86.94B |
| August 18, 2026 | 83.78B |
| August 17, 2026 | 83.33B |
| August 14, 2026 | 83.08B |
| August 13, 2026 | 83.34B |
| August 12, 2026 | 82.51B |
| August 11, 2026 | 82.41B |
| August 10, 2026 | 83.55B |
| August 07, 2026 | 81.10B |
| August 06, 2026 | 79.84B |
| August 05, 2026 | 79.47B |
| August 04, 2026 | 78.65B |
| August 03, 2026 | 78.51B |
| July 31, 2026 | 78.86B |
| July 30, 2026 | 76.34B |
| July 29, 2026 | 71.91B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| Gilead Sciences, Inc. | 182.24B |
| Alnylam Pharmaceuticals, Inc. | 30.01B |
| Amgen, Inc. | 223.31B |
| Incyte Corp. | 22.80B |
| Vertex Pharmaceuticals, Inc. | 128.10B |
Market Cap Related Metrics
| PE Ratio | 18.34 |
| PS Ratio | 5.116 |
| PEG Ratio | 9.387 |
| Price to Book Value | 2.420 |
| Price to Free Cash Flow | 22.23 |
| Price | 742.12 |
| Earnings Yield | 5.45% |
| PEGY Ratio | 7.479 |
| Operating PE Ratio | 19.04 |
| Normalized PE Ratio | 17.30 |